AstraZeneca gains rights to Eccogene’s cardiometabolic disease drug in deal worth over $1.8bn - PMLiVE AstraZeneca gains rights to Eccogene’s cardiometabolic disease drug in deal worth over $1.8bn The oral candidate could offer more dosing convenience over current injectable therapies www.pmlive.com AstraZeneca pays $185M to reenter obesity race, drops SCD drug (fiercebiotech.com) AstraZeneca pays $185M upfront to reenter oral obesity gold rush, drops phase 2 sickle cell drug AstraZeneca is buyi...
#
Astrageneca
#
ECC5004
#
ECCOGENE
#
GLP1agonist
#
Happydrug
#
obesity
